Ateganosine (THIO)

First-in-class cancer telomere targeting agent

Ateganosine (aka THIO, 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development.

Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. Ateganosine’s (THIO) in vitro activity has been studied in models of several tumor types with active telomerase.

A New Therapeutic Strategy

Ateganosine (THIO) is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, ateganosine (THIO) compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.

Low doses of ateganosine (THIO), followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment.

These results demonstrate how the ateganosine-produced (THIO-produced) telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining our telomere-targeted therapy with immunotherapy (Mender et al., 2020).

Clinical Development

MAIA is currently advancing ateganosine (THIO) in a Phase 2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This is the first study to test ateganosine’s (THIO) immune system activation followed by administration of the checkpoint inhibitor cemiplimab, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of ateganosine (THIO) administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor.

Ateganosine (THIO) followed by Libtayo for the treatment of advanced non-small cell lung cancer is in clinical development, and THIO and/or its administration with Libtayo have not yet been proven to be safe and effective.

Sources & Literature

Mender et al., Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Cancer Cell (2020), https:// doi.org/10.1016/j.ccell.2020.05.020 https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30270-1

Mender et al. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells. Oncoscience. 2015 Aug 22;2(8):693-5. https://www.ncbi.nlm.nih.gov/pubmed/26425659

Mender, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer Discovery. 2015 Jan;5(1):82-95. https://www.ncbi.nlm.nih.gov/pubmed/25516420

Mender et al. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 2018 Aug;20(8):826-837. https://www.ncbi.nlm.nih.gov/pubmed/30015158

Reyes-Uribe et al. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene. 2018 Jul;37(30):4058-4072. https://www.ncbi.nlm.nih.gov/pubmed/29695835

Sengupta et al. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul;17(7):1504-1514. https://www.ncbi.nlm.nih.gov/pubmed/29654065

Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019 May;20(5):299-309. https://www.ncbi.nlm.nih.gov/pubmed/30760854

Zhang et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. https://www.ncbi.nlm.nih.gov/pubmed/29563139

Zhang G, Shay JW. Inducing rapid telomere irreparable damage in telomerase-expressing cancers. Oncotarget. 2018 Nov 9;9(88):35803-35804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254679/

Collaboration Inquiries:

info@maiabiotech.com